Questions? We’re here to help:

+1 516-483-1196 or +44 1444 707333

Contact Us

Register for our live webinar
How and When to Evaluate BSEP Inhibition to Help Reduce
Human DILI Risk: ITC Recommendations 

Date: Thursday, July 18th, 2019
Time: 11 am ET, 8 am PT, 4 pm GMT

Inhibition of the Bile Salt Export Pump (BSEP), which is a membrane transport protein present in the liver, is now considered to be one of several important mechanisms by which drug induced liver injury (DILI) may arise in humans. Recently the International Transporter Consortium (ITC) issued pragmatic recommendations on experimental methods that can be used to assess BSEP inhibition during drug development, and thereby to reduce and manage DILI risk.

Attend our webinar to hear Dr. Gerry Kenna’s presentation, “How And When To Evaluate BSEP Inhibition To Help Reduce Human DILI Risk: ITC Recommendations”. Dr. Kenna will discuss the ITC guidance on assessing BSEP inhibition during the drug development process in order to reduce and manage DILI risk.

  • Adapt in vitro liver models for high-throughput drug discovery
  • Drug discovery limitations using hepatic models
  • Use of high-content imaging in research

Dr Kenna

Gerry Kenna, Ph.D. FBTS
Pharmaceutical Director, Safer Medicines Trust

Gerry Kenna is Pharmaceutical Director of Safer Medicines Trust, a drug safety consultant and Vice President of the Board of Trustees of the Evidence Based Toxicology Collaboration. His work is focused on developing and implementing novel, human biology-based methods that can improve human drug safety evaluation. Previously he was a toxicologist in the pharmaceutical and agrochemical industries for 15 years, having led academic research teams that explored mechanisms underlying serious human adverse drug reactions for 19 years. Dr. Kenna received B.Sc. and Ph.D. degrees in biochemistry from the Universities of Leeds and London, respectively.

Register Now